Aquestive Therapeutics, Inc. (AQST) earnings
AQST earnings moved a median of 0.00% by the close. Quarterly and annual AQST reports and results, each read against the price at its own news timestamp. Back to the AQST overview →
33 measured AQST earnings events.
Where these AQST earnings landedvs 31 measured AQST earnings reactions
| Middle 50% of AQST earnings reactions | -4.90% to +2.53% |
|---|---|
| Median reaction (to close) | 0.00% |
| Measured reactions | 31 |
Point-in-time · zero look-ahead
Half of the 31 AQST earnings events with a measured close landed between -4.90% and +2.53%; 45% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | +4.49% | +0.47% | |
| Form 10-Q Aquestive Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +4.49% | +0.47% | |
| Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET | Press release | -0.13% | -3.74% | |
| Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | -2.00% | -0.42% | |
| Form 10-Q Aquestive Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -2.00% | -0.42% | |
| Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET | Press release | +0.24% | +1.44% | |
| Form 10-K Aquestive Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +3.99% | +0.00% | |
| Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET | Press release | -0.13% | +3.02% | |
| Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | +0.65% | -5.40% | |
| Form 10-Q Aquestive Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.65% | -5.40% | |
| Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET | Press release | +0.87% | +1.89% | |
| Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | +0.00% | — | |
| Form 10-Q Aquestive Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | — | |
| Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET | Press release | +0.82% | +4.96% | |
| Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | -1.96% | -10.20% | |
| Form 10-Q Aquestive Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -1.96% | -10.20% | |
| Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET | Press release | -0.68% | +2.04% | |
| Form 10-K Aquestive Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +5.58% | +4.88% | |
| Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET | Press release | -1.80% | +0.33% | |
| Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | -4.79% | -4.90% | |
| Form 10-Q Aquestive Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -4.79% | -4.90% | |
| Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET | Press release | -4.03% | -0.20% | |
| Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | -1.10% | -5.77% | |
| Form 10-Q Aquestive Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -1.10% | -5.77% | |
| Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET | Press release | +1.99% | +10.63% | |
| Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | -5.36% | -2.99% | |
| Form 10-Q Aquestive Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -5.36% | -2.99% | |
| Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET | Press release | -2.04% | +0.00% | |
| Form 10-K Aquestive Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -8.74% | +22.68% | |
| Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET | Press release | -0.38% | -5.64% | |
| Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | -0.60% | +3.01% | |
| Form 10-Q Aquestive Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -0.60% | +3.01% | |
| Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET | Press release | -1.99% | +3.97% |
Keep exploring
More AQST: analyst actions → · SEC filings → · AQST overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| INSYS THERAPEUTICS (INSY) | 731 | +0.00% | 50% |
| Myovant Sciences Ltd. Common Shares (MYOV) | 728 | 0.00% | 49% |
| RETROPHIN INC (RTRX) | 723 | +0.06% | 52% |
| IsoRay, Inc. (DE) (ISR) | 722 | -0.01% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.